Physician profile
Edwin K King
NPI 1033180484
$10,697.98
in general payments reported to CMS, 2019-2025
46 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,904 · 2020: $1,296 · 2021: $1,747 · 2022: $1,667 · 2023: $1,380 · 2024: $1,413 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,064 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,064.11 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,929.16 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $1,210.59 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,080.80 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $996.34 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $753.86 | 2019-2022 | |
| Abbvie INC. | $664.35 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $600.35 | 2019-2025 | Belsomra, Segluromet, Steglatro |
| Novo Nordisk INC | $525.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $469.78 | 2021-2025 | |
| Astellas Pharma US INC | $255.00 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $167.82 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $166.70 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $159.97 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $140.45 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.48 | 2019-2025 | Xifaxan |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.